Boston Globe

News & Analysis

biotechnology and boston globe - All News and Analysis

• "Liberated" Fallujah as a "model city"

  - 2004-12-27

  "The US military is drawing up plans to keep insurgents from regaining control of this battle-scarred city, but returning residents may find that the measures make Fallujah look more like a police state than the democracy they have been promised," reported a December 5 Boston Globe dispatch from Iraq. ...

  Tags: Biotechnology, Boston Globe, democracy, Iraq, PRODUCTIVITY

• Distributors' plan for fees may raise price of cancer drugs.

  - 2004-12-04

  By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Dec. 4--Cancer drug distributors are trying to charge storage and handling fees to the makers of the drugs, a move some consumer groups worry could undermine parts of the Medicare prescription benefit law...

  Tags: Biotechnology, Boston Globe, HEALTHCARE, Medicare, wholesaler

• SEC begins formal investigation of Newton, Mass.-based biotech company.

  - 2004-11-30

  By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Nov. 30--The US Securities and Exchange Commission has upgraded its investigation of Pro-Pharmaceuticals Inc. of Newton from an informal inquiry to a formal probe, according to the firm's most recent quarterly...

  Tags: Biotechnology, Boston Globe, FINANCE, Investment, Pro-Pharmaceuticals Inc., SEC, stock, U.S. Department of Labor

• Opening of Fall River, Mass., drug development facility stirs political debate.

  - 2004-11-06

  By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Nov. 6--Avant Immunotherapeutics Inc. says the new drug development facility it opened yesterday in Fall River is state of the art, technically. How it fits into the state's economic development...

  Tags: Biotechnology, Boston Globe, HEALTHCARE, vaccine

• Pay for Cambridge, Mass.-based drug developer's CEO was tops in biotech field.

  - 2004-10-27

  By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Oct. 27--Genzyme Corp. chief executive Henri A. Termeer's salary of $1.2 million last year was the highest of any in the biotechnology industry, according to a survey released yesterday. ...

  Tags: Benefits, Biotechnology, Boston Globe, Cambridge, CEO, compensation, developer, Genzyme Corp., salary

• Former Massachusetts house speaker focuses on biotechnology in new role.

  - 2004-10-11

  By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Oct. 11--Former House speaker Thomas M. Finneran is the new president of the Massachusetts Biotechnology Council, a trade group that counts more than 400 members, including Genzyme Corp. and Biogen Idec...

  Tags: Biotechnology, Boston Globe, stem-cell

• Massachusetts House speaker issues 'bittersweet' farewell.

  - 2004-09-29

  By Raphael Lewis, The Boston Globe Knight Ridder/Tribune Business News Sep. 29--Departing House Speaker Thomas M. Finneran vowed yesterday to "cajole, plead, or beg" lawmakers in his new role as president of the Massachusetts Biotechnology Council, but left the door open...

  Tags: Biotechnology, Boston, Boston Globe, council, Governor, president, speaker

• Dutch drug maker to set up Cambridge, Mass.-area lab, hire 30 scientists.

  - 2004-09-09

  By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Sep. 9--Dutch drug conglomerate Akzo Nobel NV is planning to set up a research laboratory in East Cambridge, joining a growing list of pharmaceutical firms that have established outposts to tap Greater...

  Tags: Biotechnology, Boston Globe, Cambridge

• Bedford, Mass., biotech firm's relocation needs to be done quickly, carefully.

  - 2004-08-15

  By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Aug. 15--BEDFORD, Mass. -- Scientists at NitroMed Inc. hope their experimental drugs will cure heart disease someday. But lately their focus has been on more mundane matters. How fast could...

  Tags: Biotechnology, Boston Globe, scientist

• Money flows to New England firms in best funding round since 2001.

  - 2004-08-09

  By Robert Weisman, The Boston Globe Knight Ridder/Tribune Business News Aug. 9--The big VC deals are back. New England's top three recipients of venture funds in the second quarter -- TechTarget Inc., Altus Pharmaceuticals Inc., and Microbia Inc. -- raised...

  Tags: Altus Pharmaceuticals Inc., Biotechnology, Boston Globe, FINANCE, Government, Investment, TechTarget